To the best of our knowledge and literature review, this is the first case of BRAF V600E mutated GBM with the acquisition of KRASG12 D and NF1L1083R mutation both in the RAS/MAPK pathway and histologic transformation to gliosarcoma as a resistance mechanism to BRAF/MEK inhibition. The gene discussed is MAP2K7; the disease is gliosarcoma.